Piramal Pharma Solutions breaks ground on $90 mn US expansion

Piramal Pharma Solutions breaks ground on $90 mn US expansion

Piramal Pharma Solutions, one of India's leading contract development and manufacturing organization (CDMO), on Monday said it is investing $90 million to expand two of its U.S. facilities located in Riverview, Michigan, and Lexington, Kentucky.

This investment aims to add commercial-scale manufacturing capabilities and enhance the capacity and efficiency of both sites.

Both facilities are integral to Piramal Pharma's integrated antibody-drug conjugate (ADC) offering, ADCelerate™.

The Riverview, Michigan facility specializes in drug substance development and manufacturing, including high potency active pharmaceutical ingredients (HPAPIs). It is a key part of providing payload-linkers crucial for antibody drug conjugate (ADC) therapies. ADC are drugs that combine chemotherapy and monoclonal antibody.

The expansion at this site will include a commercial-scale suite for payload-linker development and manufacturing, expected to be operational by the end of 2025.

The Lexington, Kentucky facility is Piramal Pharma's dedicated fill/finish site for sterile injectable drug products, offering sterile compounding, liquid filling, and lyophilization. This site provides fill/finish services for all integrated programs, including ADC projects. The expansion will add 24,000 square feet of manufacturing space, a new laboratory, and advanced machinery, such as a new filling line, two commercial-size lyophilizers, a specialized capping machine, and an external vial washer. This expansion is anticipated to be completed by late 2027. Upon completion, the Lexington site's manufacturing capacity will more than double, increasing from 104 product batches per year to over 240 annual batches.

The Lexington facility expansion is also expected to create 40 new full-time jobs, contributing to the local economy and strengthening Piramal Pharma's workforce.

This investment aligns with the trend toward U.S. onshore manufacturing, reinforcing the company's dedication to domestic production and supply chain resilience.

Piramal Pharma held a groundbreaking ceremony for the Lexington facility expansion on June 25, 2025.

This investment comes as the sterile injectables market is experiencing significant growth due to increased medical necessity, broader regulatory approvals, and advancements in R&D. Additionally, ADC therapies are gaining traction with ongoing innovation, wider regulatory acceptance, and demonstrated effectiveness. Piramal

Pharma aims to capitalize on these trends, meet rising demand, and enhance its competitive edge.

Nandini Piramal, Chairperson, Piramal Pharma, stated that the sterile injectables market is projected to exceed $20 billion by 2028, highlighting the need for enhanced offerings in this segment.

Peter DeYoung, Chief Executive Officer, Piramal Global Pharma, emphasized the rapid emergence of ADCs as effective precision immunotherapy for cancers and tumors, and the company's commitment to adapting its services to meet this growing demand.

Lexington Mayor Linda Gorton expressed enthusiasm for the project, noting it positions Lexington as a strong business environment and a developing leader in the pharmaceutical industry.